Comparative Pharmacology
Head-to-head clinical analysis: APONVIE versus EMRELIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APONVIE versus EMRELIS.
APONVIE vs EMRELIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
APONVIE (pemigatinib) is a selective fibroblast growth factor receptor (FGFR) inhibitor. It binds to and inhibits FGFR1, FGFR2, and FGFR3, thereby suppressing FGFR signaling and reducing proliferation and survival of tumor cells with FGFR alterations.
Emrelis is a monoclonal antibody that inhibits the interaction between programmed cell death protein 1 (PD-1) and its ligands PD-L1 and PD-L2, thereby activating T-cell-mediated antitumor immune response.
APONVIE is not a recognized drug; no dosing information available.
100 mg subcutaneously once weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours in healthy adults; prolonged to 24–36 hours in severe renal impairment (CrCl <30 mL/min).
12 hours (terminal); dosing interval adjusted in renal impairment (CrCl <30 mL/min)
APONVIE is primarily excreted renally as unchanged drug (approx. 70%) and via biliary/fecal routes (approx. 30%).
Renal: 70% unchanged; fecal: 15%; biliary: 10%
Category C
Category C
Antiemetic
Antiemetic